Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,345 shares of the pharmaceutical company’s stock after acquiring an additional 2,576 shares during the period. Vertex Pharmaceuticals accounts for approximately 1.3% of Greenwood Capital Associates LLC’s investment portfolio, making the stock its 13th biggest holding. Greenwood Capital Associates LLC’s holdings in Vertex Pharmaceuticals were worth $10,313,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after buying an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. increased its holdings in Vertex Pharmaceuticals by 3.9% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock valued at $259,000 after buying an additional 24 shares in the last quarter. Hohimer Wealth Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 0.8% during the 4th quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock worth $1,193,000 after acquiring an additional 24 shares in the last quarter. Johnson Financial Group Inc. grew its position in shares of Vertex Pharmaceuticals by 2.5% during the 4th quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock valued at $407,000 after acquiring an additional 24 shares during the period. Finally, Arthur M. Cohen & Associates LLC raised its holdings in Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on VRTX shares. Piper Sandler increased their target price on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. BMO Capital Markets upped their price target on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 7th. UBS Group reduced their target price on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $462.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $438.48.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 1,565 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $457.00, for a total value of $715,205.00. Following the transaction, the chief executive officer now directly owns 121,374 shares of the company’s stock, valued at approximately $55,467,918. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Bruce I. Sachs sold 7,073 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $17,920,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Reshma Kewalramani sold 1,565 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $457.00, for a total transaction of $715,205.00. Following the completion of the sale, the chief executive officer now directly owns 121,374 shares in the company, valued at $55,467,918. The disclosure for this sale can be found here. Insiders sold 26,086 shares of company stock worth $11,983,266 over the last 90 days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Trading Up 0.4 %

Shares of Vertex Pharmaceuticals stock opened at $480.73 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. The company has a market capitalization of $124.05 billion, a P/E ratio of 31.20, a PEG ratio of 2.47 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1 year low of $335.82 and a 1 year high of $486.42. The company’s fifty day moving average is $430.15 and its two-hundred day moving average is $418.87.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The firm had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. During the same quarter in the previous year, the firm posted $2.67 EPS. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.